colon cancer
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with XELOX + bevacizumab therapy plan It is a colon cancer (2) histologically has been confirmed I have one or more measurable liver metastatic lesions (3) major axis more than 1cm From adjuvant chemotherapy end however (which is a healing unresectable colorectal cancer progression of recurrence (4) initial drug therapy Recurrence have passed more than six months is regarded as the first drug therapy) Is 20 years of age or older age (5) obtaining informed consent at the time Is 0 ~ 1 (6)The Eastern Cooperative Oncology Group is (ECOG) Performance Status (7) This test content, written consent of the person has been obtained
Exclusion criteria
Exclusion criteria: (1) On the image, brain metastases are found, or from clinical symptoms, brain metastasis is suspected. (2) Cerebrovascular neuropathy, or with a history within one year prior to enrollment. It has been conducted surgery within 4 weeks. (3)Prior to enrollment, biopsy with incision, the suture treatment for trauma, or have implemented fine-needle aspiration cytology within 1 week. (4) Traumatic fracture not healing (5) Bleeding tendency, or to have a coagulopathy. (6)The administration of an anti-thrombotic agent for thrombosis within 10 days before registration (7) Require the administration of aspirin formulation of 325 mg or more. (8) It has with symptoms at the time of registration and the (corresponding to grade 2 or more in Ver.3.0 Japanese translation JCOG / JSCO version NCI-CTCAE) heart disease or are doing some kind of treatment. Alternatively, there is a history of myocardial infarction within one year prior to enrollment. (9) on the image, a body cavity fluid requiring treatment. (10)Digestive cancer carcinoma in situ of the cervix and skin basal cell carcinoma, or by endoscopic mucosal resection endoscopic, healing has been confirmed, transition is not observed overlap cancer of less than five years was (healing disease-free interval it has to a) except for the prostate cancer (11) And has a neuropathy of grade 1 or more Ver.3.0 Japanese translation JCOG / JSCO version NCI-CTCAE (12)Pregnant women, lactating women, pregnancy test positive. Or, patients with no intention to contraception. (13) Oxaliplatin, or with a history of hypersensitivity to severe capecitabine (14) Suspected (DPD) deficiency dihydropyrimidine dehydrogenase, adverse reactions to fluoropyrimidine drugs was expressed. (15)Investigator deems inappropriate to participate in the test (16)The cases with serious complications (uncontrolled digestive ulcer, hypertension, diarrhea, infections, gastrointestinal perforation, such as interstitial pneumonia or pulmonary fibrosis)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS,ORR,Safety | — |
Countries
Japan
Contacts
Public ContactKazuhisa Takeda
Yokohama City University Hospital gastroenterological surgery
Outcome results
None listed